Search: onr:"swepub:oai:DiVA.org:uu-81295" >
Phase II study of c...
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
- Article/chapterEnglish2004
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-81295
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-81295URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
Subject headings and genre
-
Adolescent
-
Adult
-
Aged
-
Anthracyclines/therapeutic use
-
Antineoplastic Agents/therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
-
Breast Neoplasms/*drug therapy/mortality
-
Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives
-
Disease Progression
-
Female
-
Humans
-
Maximum Tolerated Dose
-
Middle Aged
-
Paclitaxel/administration & dosage/adverse effects
-
Survival Rate
-
Treatment Outcome
Added entries (persons, corporate bodies, meetings, titles ...)
-
Perez-Manga, G
(author)
-
Constenla, M
(author)
-
Ruiz, A
(author)
-
Carabantes, F
(author)
-
Castellanos, J
(author)
-
Gonzalez Baron, M
(author)
-
Villman, K
(author)
-
Söderberg, M
(author)
-
Ahlgren, JUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Centrum för klinisk forskning, Gävleborg
(author)
-
Casinello, J
(author)
-
Regueiro, P
(author)
-
Murias, A
(author)
-
Uppsala universitetInstitutionen för onkologi, radiologi och klinisk immunologi
(creator_code:org_t)
Related titles
-
In:Br J Cancer90:9, s. 1740-60007-0920
Internet link
Find in a library
To the university's database
- By the author/editor
-
Batista, N
-
Perez-Manga, G
-
Constenla, M
-
Ruiz, A
-
Carabantes, F
-
Castellanos, J
-
show more...
-
Gonzalez Baron, ...
-
Villman, K
-
Söderberg, M
-
Ahlgren, J
-
Casinello, J
-
Regueiro, P
-
Murias, A
-
show less...
- Articles in the publication
-
Br J Cancer
- By the university
-
Uppsala University